cbdMD, Inc. announced that it has formed cbdMD Therapeutics LLC (cbdMD Therapeutics), a newly formed wholly-owned subsidiary of the Company for the purposes of isolating and quantifying the Company’s ongoing investments in science related to its existing and future products, including research and development activities for therapeutic applications. The Company also announced that Dr. Sibyl Swift, former U.S. Food and Drug Administration (FDA) official, who serves as a regulatory consultant to the Company, and Lance Blundell, Esq. the Company’s General Counsel, will serve as Co-Chairs of cbdMD Therapeutics. The Company previously announced in February 2020 that Dr. Swift had been engaged as a regulatory consultant to oversee the Company’s regulatory initiatives and prepare its products for further certifications. From 2014 to 2020, Dr. Swift served in various capacities at the FDA. Prior to joining the FDA, from 2012 to 2014, Dr. Swift was a research biochemist within the Department of Defense (DOD) at the Armed Forces Radiobiology Research Institute (AFRRI) and an Adjunct Assistant Professor at the Department of Military Emergency Medicine at the Uniformed Services University of the Health Sciences (USUHS). In her role at AFRRI, she explored potential countermeasures and investigational new drugs (INDs) for their therapeutic potential and also potential toxicity.